Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Vectibix Cap Cuts Patient Cost, But Will Payers Balk At High Price?

Executive Summary

Amgen announced a program to limit patients' out-of-pocket cost for Vectibix, following FDA approval of panitumumab Sept. 27.

You may also be interested in...



Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs

Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.

Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs

Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.

Avastin Growth Cut By Colorectal Cancer Competition, Genentech Says

Avastin (bevacizumab) utilization in second-line metastatic colorectal cancer is taking a hit from competitor products, Genentech reported during its April 11 first-quarter earnings call

Related Content

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel